ABOUT MEMO THERAPEUTICS AG
Memo Therapeutics AG
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology.
We have identified potent SARS-CoV-2-neutralizing antibodies
Memo Therapeutics AG will do a comprehensive analysis of the antibody repertoires of patients who have recovered from SARS-CoV-2 infection using our proprietary technology. The resulting discovery of ultra-rare but highly neutralizing antibodies will be used for the development of therapeutic antibodies as well as rational vaccine strategies.